Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

New “package” to help treat people with Epilepsy

Doctors given new “package” to help treat people with epilepsy

PHARMAC has announced a series of changes that will give doctors more resources to treat people with epilepsy.

The package means it is going to be easier for patients to be prescribed the new style epilepsy medicines, and it also means any GP can prescribe these new treatments.

This follows a series of improvements in the area of epilepsy treatment, with PHARMAC actively surveying doctors to find out what they thought was needed in this area.

PHARMAC Medical Director Peter Moodie says the move reflects PHARMAC’s aim to make sure doctors have the resources they need to effectively treat epilepsy.

“We surveyed doctors to find out what was needed for better treatment of patients with epilepsy – and we’ve taken on board what they have told us.”

Peter Moodie says as a result more people with epilepsy now have access to more new treatments than ever before.

PHARMAC has announced it will fully fund topiramate (pron:toe-PUR-a-mate) from September 1. This means patients now have access to three fully funded new anti-epilepsy drugs, with the other two new drugs being lamotrigine and vigabatrin. Besides these, there are 12 older style anti-epilepsy drugs used to manage the illness.

He says spending on these new epilepsy drugs has also increased almost five-fold in the last five years – despite the number of patients staying stable.

“Although the number of people with epilepsy hasn’t increased in the past five years, the amount spent on subsidised new drugs for epilepsy has grown in that time from $950,000 to $4.35 million this year.”

Peter Moodie says another positive development is that now any GP can write a prescription for the three anti-epilepsy drugs. Previously, only approved doctors could prescribe these drugs. Although the initial treatment must still be approved by a specialist, which was also the case previously.

“These decisions are all part of PHARMAC’s ongoing commitment to ensure patients with epilepsy are getting the best possible treatment they can. More patients are going to have access to newer agents, while the fact that any GP can prescribe adds to the widened access.”

About 27,000 New Zealanders have epilepsy, and currently about 2000 patients are being treated by one of the newer agents. It is estimated that following the decision to fund topiramate the numbers will triple to about 6000.
[ends]

For further information, please phone (025) 429 212.

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Media Mega Merger: StuffMe Hearing Argues Over Moveable Feast

New Zealand's two largest news publishers are appealing against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Elsewhere:


Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>

ALSO:


Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>

ALSO:

Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>